Injective drops more than 12% after SEC transfer agent status and ETF applications in focus

Traders Union
All News
Crypto
Injective slides 12.26% to $7.16 today

Highlights

Injective registered with the SEC as a transfer agent, expanding tokenized asset offerings to pre-IPO shares including SpaceX and OpenAI.
Nearly half of Injective’s 135 markets now support tokenized real-world assets, with trading volume above $5.3 billion.
INJ/USD faces short-term selling pressure but holds above key medium- and long-term support, with a projected 5-day range of $6.3 to $8.83 and 70% probability of an upward move.

Tokenized asset expansion and ETF reviews as price lags positive flows

Injective recently registered as a transfer agent with the US Securities and Exchange Commission, expanding its ability to offer tokenized assets including pre-IPO shares from companies such as SpaceX and OpenAI. Gulf Labs joined as an institutional validator, contributing to network security and governance. Three US-based ETF applications linked to Injective remain under SEC review, and nearly half of Injective’s 135 markets now support tokenized real-world assets, with trading volume surpassing $5.3 billion. These developments occurred, though price action has remained under broader selling pressure.

Anton Kharitonov, an expert at Traders Union, views the recent 12.26% drop in Injective (INJ) as a warning sign. He notes the decline beneath the 20-day moving average and questions the strength of buyer support despite positive institutional news. Kharitonov highlights persistent short-term selling pressure, with mixed signals from daily indicators suggesting unstable sentiment. He is critical of overbought readings and sees the downside gap as a sign of risk prevailing. "INJ’s price action and volatility prove the market is still wary — I would remain defensive until buyers confirm sustained control."

Viktoras Karapetjanc, an expert at Traders Union, sees structural positives for Injective despite the recent pullback. He points to SEC registration, institutional validator growth, and real-world asset expansion as strengthening fundamentals. Karapetjanc believes robust trading volumes and ETF prospects set the stage for recovery. He is confident the bullish structure remains intact above the 50-day average. "The market is offering growth opportunities in INJ — structural drivers support further upside in the medium term."

Sholanke Dele, market strategist, notes that overall sentiment for INJ remains fragile. He emphasizes that short-term volatility and a sharp early selloff have undermined trader confidence. Dele is skeptical about the market absorbing recent institutional news amid heavy downside pressure. "I remain cautious here — volatile swings and weak intraday sentiment show buyers still lack conviction."

Competing technical signals amid downside gap and resilient buyer momentum

INJ/USD trades below the 20-day moving average at $7.59, but remains above both the 50-day at $6.64 and the 200-day at $5.07. This configuration signals short-term selling pressure, but the medium- and long-term trends are still constructive, with bullish alignment between the 50- and 200-day averages. Immediate resistance stands at the near-term ceiling of $7.17, with support at the near-term floor of $6.75. The Ichimoku Kijun at $7.55 acts as further resistance. Daily momentum indicators show mixed signals. The MACD and ADX both lean bullish. The RSI at 54.41 issues a buy signal, the CCI also signals buy, and the Awesome Oscillator confirms upward momentum. However, the Stochastic RSI gives a sell signal, and the Hull Moving Average suggests selling sentiment. Bull/Bear Power value at 0.83 shows buyers dominate intraday action, although it is flagged as overbought. The pair is down $1 from the previous close, a drop of 12.26% after a downside gap of nearly 6%. Price action is near session lows and intraday volatility stands at 7.39%. Early downside and volatility highlight pressure after the open, yet momentum signals indicate interest from buyers.

Previously it was reported that Injective’s SEC registration and ongoing technical weakness suggested near-term caution despite improved regulatory positioning. The current analysis adds that, while short-term selling pressure persists, prevailing technical indicators highlight a sideways consolidation scenario, with $7.17 as the key resistance and $6.75 as critical support to monitor.

Source of Data: INJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.